• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.

作者信息

Messori A, Cecchi M, Becagli P, Trippoli S

出版信息

Cancer. 1997 Jun 1;79(11):2264-6. doi: 10.1002/(sici)1097-0142(19970701)79:11<2264::aid-cncr29>3.0.co;2-s.

DOI:10.1002/(sici)1097-0142(19970701)79:11<2264::aid-cncr29>3.0.co;2-s
PMID:9179077
Abstract
摘要

相似文献

1
Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.紫杉醇作为晚期卵巢癌患者一线治疗药物的药物经济学概况。一项终身成本效益分析。
Cancer. 1997 Jun 1;79(11):2264-6. doi: 10.1002/(sici)1097-0142(19970701)79:11<2264::aid-cncr29>3.0.co;2-s.
2
Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.紫杉醇：对其用于治疗卵巢癌的药物经济学综述
Pharmacoeconomics. 2001;19(12):1227-59. doi: 10.2165/00019053-200119120-00005.
3
Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.紫杉醇作为晚期卵巢癌患者一线治疗药物的药物经济学概况。一项终生成本效益分析。
Cancer. 1996 Dec 1;78(11):2366-73.
4
Pharmacoeconomic profile of taxanes in advanced ovarian cancer.紫杉烷类药物在晚期卵巢癌中的药物经济学概况
Anticancer Drugs. 1998 Nov;9(10):909-16. doi: 10.1097/00001813-199811000-00010.
5
Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer.衡量晚期卵巢癌患者对多西他赛的治疗偏好及支付意愿。
Pharmacoeconomics. 2004;22(6):375-87. doi: 10.2165/00019053-200422060-00004.
6
Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer.
J Clin Oncol. 1997 Feb;15(2):640-5. doi: 10.1200/JCO.1997.15.2.640.
7
[A new, more expensive agent against ovarian cancer. Worth its price?].[一种新型、更昂贵的抗卵巢癌药物。物有所值吗？]
Lakartidningen. 1997 Jan 8;94(1-2):21-4.
8
NICE approves Taxol for ovarian cancer.英国国家卫生与临床优化研究所批准紫杉醇用于治疗卵巢癌。
BMJ. 2000 May 13;320(7245):1293.
9
Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.将紫杉醇用作晚期卵巢癌一线治疗的经济和政策影响：安大略省的视角
J Clin Oncol. 1997 Feb;15(2):632-9. doi: 10.1200/JCO.1997.15.2.632.
10
Paclitaxel and docetaxel. Innovation, but at what cost?
Pharmacoeconomics. 1995 Jul;8(1):1-4. doi: 10.2165/00019053-199508010-00001.

引用本文的文献

1
Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review.胰腺癌一线化疗方案的经济学评估：一项批判性综述。
Pharmacoeconomics. 2017 Jan;35(1):83-95. doi: 10.1007/s40273-016-0452-6.
2
Lifetime cost-utility analysis of patients with refractory epilepsy treated with adjunctive topiramate therapy : cost-effectiveness in refractory epilepsy.伴有附加托吡酯治疗的耐药性癫痫患者的终生成本-效用分析：耐药性癫痫的成本效益。
Clin Drug Investig. 2003;23(4):225-32. doi: 10.2165/00044011-200323040-00002.
3
From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.
从随机临床试验到临床实践：紫杉醇用于晚期卵巢癌一线治疗的实用成本效益分析
Pharmacoeconomics. 2004;22(10):633-41. doi: 10.2165/00019053-200422100-00002.
4
Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.紫杉醇：对其用于治疗卵巢癌的药物经济学综述
Pharmacoeconomics. 2001;19(12):1227-59. doi: 10.2165/00019053-200119120-00005.